Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
MaRS Innovation [Editor's Note: Link is no longer available] is partnering with Dr. James Eubanks of Krembil Research Institute to develop a new treatment for Rett syndrome, a rare developmental disorder found almost exclusively in girls and women.
Infants with Rett syndrome develop and grow normally until the age of eight to 12 months when symptoms begin appearing.
Although the symptoms vary in type and severity, most of the girls and women with the disorder cannot speak or use their hands purposefully. Many also experience seizures that are difficult to control with medications.
There is no cure for Rett syndrome, and the available treatments can only help alleviate symptoms.
Researchers have known for many years that most cases of Rett syndrome are caused by mutations in the MECP2 gene; however, the mechanisms that link these genetic changes to the syndrome's diverse symptoms are not well understood.
"We believe that we have discovered an important piece of the puzzle," says Dr. Eubanks, a Senior Scientist at Krembil, UHN, who has been studying the disorder for more than 20 years.
Support creation and evaluation of drug-like compounds
Using experimental models, Dr. Eubanks and his team have shown that MECP2 mutations lead to abnormally high levels of the TRPM2 protein in the brain, which interfere with normal brain development and function. Although this mechanism is likely to be only one of several contributing to the disorder and its symptoms, the researchers have accumulated compelling evidence that it is an important contributor and represents a promising therapeutic target for Rett syndrome.
MaRS Innovation will initially invest up to $400,000 to help translate Dr. Eubanks' discovery into a new treatment for Rett syndrome. The funds will support the creation and evaluation of drug-like compounds that target TRPM2, dampening its activity, in the brain of Rett patients.
Dr. Mark Reed, a medicinal chemist and head of Krembil's Centre for Medicinal Chemistry and Drug Discovery, will oversee the work, which will be split between the Centre and the Charles River Discovery site in the United Kingdom.
The new partnership will also give Drs. Eubanks and Reed access to MaRS Innovation commercialization services to support further development of any promising treatments.
"This is a unique and exciting opportunity to really help patients by developing a treatment that is more effective than what is currently available to them," says Dr. Eubanks.